Aktis Oncology (NASDAQ:AKTS) Stock Price Down 10% – Should You Sell?

Aktis Oncology (NASDAQ:AKTS)’s share price fell 10% on Monday . The stock traded as low as $30.12 and last traded at $28.5720. 53,438 shares traded hands during mid-day trading, a decline of 84% from the average session volume of 334,355 shares. The stock had previously closed at $31.76.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on AKTS. William Blair started coverage on shares of Aktis Oncology in a research report on Wednesday, April 29th. They set an “outperform” rating on the stock. Weiss Ratings upgraded shares of Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 23rd. HC Wainwright increased their price target on Aktis Oncology from $33.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, June 2nd. Finally, Raymond James Financial began coverage on Aktis Oncology in a report on Monday, June 15th. They issued a “strong-buy” rating and a $40.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $34.00.

Aktis Oncology Stock Performance

The firm has a market cap of $1.52 billion and a PE ratio of -75.03. The stock’s 50-day moving average price is $21.99.

Aktis Oncology (NASDAQ:AKTS) last posted its earnings results on Monday, March 30th. The technology company reported ($18.17) earnings per share for the quarter. The business had revenue of $1.87 million for the quarter. On average, sell-side analysts predict that Aktis Oncology will post -1.62 earnings per share for the current year.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.